pembrolizumab5-fluorouracilleucovorinadagrasibzenocutuzumabliposomal irinotecandaraxonrasibPancreatic ductal adenocarcinoma (PDAC)NAPOLI-1 trialconventional chemotherapy
…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…